BioMAP profiling is in vitro and high throughput characterization of the clinically relevant biological effects of test agents (small molecules, biologics, etc.) on a broad range of human disease models.
BioMAP Systems are constructed with one or more primary cell types from healthy human donors, with stimuli (such as cytokines or growth factors) added to capture defined aspects of human tissue or disease states.
BioMAP endpoints (biomarker readouts) measured in BioMAP systems are cell surface or secreted proteins selected for therapeutic and biological relevance and are detected by immuno-based techniques.
For a given test agent, the cumulative changes in biomarker readouts (above or below baseline) across a panel of BioMAP systems make up a BioMAP profile. BioMAP Profiles are highly reproducible and can distinguish features of compounds, including target selectivity, compound liabilities and mechanisms of action (MOA).
BioMAP systems are highly validated with well-characterized drugs and pharmacological agents to ensure that BioMAP systems show responses that closely mimic what is seen in the clinic and published literature. Over 4,000 bioactive agents have been tested at multiple concentrations and recorded using these systems in order to generate the BioMAP Reference Database, which provides the bioinformatic power behind the platform. In house developed software is used to mathematically compare profiles of newly run test agents to those present in the database.
Comparing the BioMAP signature of a test agent to a proprietary reference database of > 4,000 BioMAP profiles of bioactive agents (e.g., drugs, biologics, chemicals, etc.) can enable drug discovery and development in a human disease-relevant manner.
Characterization of test agents in BioMAP profiles can be used to:
(1) correlate drug effects to in vivo
(2) distinguish between multiple compounds based on MOA and target selectivity
(3) identify potential biomarkers for in vivo
(4) provide a predictive signature for in vivo
(5) benchmark against current standards of care
(6) test drug combinations
|Primary human cell-based assays
||Assays provide human translation for discovery programs with readouts that are clinically relevant
||Compounds can be compared across programs over time in the same standard assay panel
|Disease-relevant culture conditions
||Assay results are predictive of in vivo results
|Large reference drug database
||Assay systems are validated with multiple compounds from the same target class, or for the same clinical indication, etc. These compounds are a portion of the large BioMAP database library of agents available for analytical comparison against client compounds
|Predictive algorithms for relevant efficacy and safety related mechanisms
||The platform can mathematically provide identification of drug and toxicity mechanisms of action using an unbiased approach